Navigation Links
Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
Date:9/1/2008

GOTEBORG, Sweden, September 1 /PRNewswire/ -- Calabar AB, a privately held pharmaceutical company developing therapies for treating dry mouth, today announced a EUR 350,000 equity financing from the investment company Karolinska Development AB. The financing will take Calabar's product through a phase II study with repeated dosing. "We believe the unique local action of the drug on the minor glands will lead to improved outcomes in patients with dry mouth and we look forward to its continued development," remarked VP Business Development, Fredrik Rook of Calabar AB. "Dry mouth is affecting millions of people every day and there is a great unmet need for new drugs in this area."

The active drug, physostigmine, a cholinesterase inhibitor, targets the minor salivary glands with a direct local action, inducing a more lubricating saliva. In previous phase II studies with single dosing, the locally administered drug proved to significantly increase the salivary flow in patients suffering from dry mouth.

"This will take treatment of dry mouth symptoms to a new level," concludes Mr. Rook.

About Calabar

Calabar AB is a privately-held company committed to developing a pharmaceutical product addressing the great unmet needs of xerostomia "dry mouth". The company develops locally administered formulations of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of administration significantly limits adverse events. The company is part of the Karolinska Development AB portfolio. For more information, please visit http://www.calabar.se

Investor and Media Contact

Fredrik Rook,

+46-8-524-860-38,

fredrik.rook@calabar.se .


'/>"/>
SOURCE Calabar AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
2. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
3. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
4. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
5. PRoFESS(R) Results Announced at XVII European Stroke Conference
6. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
7. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
8. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
9. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
10. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
11. Light Sciences Oncology Raises $40.1 Million in Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland , ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... agreement with Therawis Diagnostics GmbH to develop and commercialize predictive ... and market PITX2 as a marker to predict effectiveness of ... patients. "We are pleased to partner with Therawis, ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... England , May 25, 2016 ... company employing the precision of circulating tumour DNA ... today announces the appointment of Professor Clive ... provide medical leadership across the clinical development programme, ... Inivata,s products help deliver significant improvements in clinical ...
Breaking Medicine Technology:
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
(Date:5/26/2016)... , ... May 26, 2016 , ... On Memorial Day, ... women who lost their lives in military battle for the country. The nonprofit ... 2015 to provide more programs that empower independence for disabled military veterans, as well ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... MadgeTech will ... designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With products ... reliable monitoring solutions trusted by government agencies, including NASA. , In 2012, NASA ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
(Date:5/26/2016)... Tampa, Fla. (PRWEB) , ... May 26, 2016 , ... ... Center (AHEC) to host a six-week smoking cessation class starting June 6 at their ... AHEC’s website, http://www.gnahec.org . , Additionally, the Lung Institute has created a free ...
Breaking Medicine News(10 mins):